Fractionated stereotactic radiotherapy boost and weekly paclitaxel in malignant gliomas clinical and pharmacokinetics results

Technology in Cancer Research and Treatment

Volumn 6, Issue 3, 2007, Pages 169-175

  Ashamalla, Hani ^a   Zaki, B ^b   Mokhtar, B ^a   Lewis, L ^b   Lavaf, A ^a   Nasr, H ^a   Colella, F ^a   Dosik, D ^a   Krishnamurthy, M ^a   Saad, N ^a   Guriguis, A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Fractionated stereotactic radiotherapy; Malignant gliomas; Paclitaxel; Pharmacokinetics

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PACLITAXEL; PHENYTOIN;

ADULT; ALLERGIC REACTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION;

EID: 34347399770     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460700600303     Document Type: Article

References (46)

1. Walker, M. D., Alexander, E., Hunt, W E. et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49, 333-343 (1978).
2. Walker, M. D., Strike, T. A., and Sheline, G. E. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5, 1725-1731 (1979).
3. Walker, M. D., Green, S. N., Byar, D. P. et al. Randomized comparison of radiotherapy and nitrosureas for malignant gliomas after surgery. N Engl J Med 303, 1323-1329 (1980).
4. Florell, R. C., MacDonald, D. R., and Irish, W D. et al. Selection bias, survival, and brachytherapy for glioma. J Neurosurg 76, 179-183 (1992).
5. Chang, C. H., Horton, J., Schoenfeld, D. et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 2, 997-1007 (1983).
6. Fine, H. A., Dear, K. B., and Loeffler, J. S. et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71, 2585-2597 (1993).
7. Bleehen, N. M. and Stenning, S. P. A Medical Cancer Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 64, 769-774 (1991).
8. Walker, M. D., Green, S. B., Byar, D. P. et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303, 1323-1329 (1980).
9. Gutin, P., Leibel, S., Wara, W. et al. Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources. J Neurosurg 67, 864-873 (1987).
10. Gutin, P. H., Prados, M. D., Phillips, T. L. et al. External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2. Int J Radiat Oncol Biol Phys 21, 601-606 (1991).
11. Leibel, S. A., Gutin, P. H., and Wara, W. M. et al. Survival and quality of life after interstitial implantation of removable high-activity Iodine- 125 sources for the treatment of patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 17, 1129-1139 (1989).
12. Loeffler, J., Alexander, E. III, and Wen, P. Y. et al. Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma. J Natl Cancer Inst 82, 1918-1921 (1990).
13. Laing, R. W., Warrington, A. P., Graham, J., Britton, J., Hines, F., and Brada, M. Efficacy and toxicity of fractionated stereotactic radiotherapy in the treatment of recurrent gliomas (phase I/II study). Radiother Oncol 27, 22-29 (1993).
14. Shepherd, S. F., Laing, R. W., and Cosgrove, V. P. et al. Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys 37, 393-398 (1997).
15. Haines, S. J. Moving targets and ghosts of the past: outcome measurement in brain tumour therapy. J Clin Neurosci 9, 109-112 (2002).
16. Hariz, M. I., Henriksson, R., Lofroth, P. O., Laitinen, L. V., and Saterborg, N. E. A non-invasive method for fractionated stereotactic irradiation of brain tumours with linear accelerator. Radiother Oncol 17, 57-72 (1990).
17. Hudes, R. S., Corn, B. W., and Werner-Wasik, M. et al. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys 43, 293-298 (1999).
18. Hall, W. A., Djalilian, H. R., and Sperduto, P. W. et al. Stereotactic radiosurgery for recurrent malignant gliomas. J Clin Oncol 13, 1642-1648 (1995).
19. Shrieve, D. C., Alexander, E., 3rd, and Black, P. M. et al. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg 90, 72-77 (1999).
20. Van Kampen, M., Engenhart-Cabillic, R., Debus, J., Fuss, M., Rhein, B., and Wannenmacher, M. Stellenwert der Radiochirurgie in der Primaertherapie des Glioblastoma multiforme. Strahlenther Onkol 174, 187-192(1998)
21. Thilmann, C., Zabel, A., Grosser, K. H., Hoess, A., Wannenmacher, M., and Debus, J. Intensity-modulated radiotherapy with an integrated boost to the macroscopic tumour volume in the treatment of high-grade gliomas. Int J Cancer 96, 341-349 (2002).
22. Shrieve, D. C., Alexander, E., 3rd, and Wen, P. Y. et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 36, 275-284 (1995).
23. Laing, R. W., Warrington, A. P., Graham, J., Britton, J., Hines, F., and Brada, M. Efficacy and toxicity of fractionated stereotactic radiotherapy in the treatment of recurrent gliomas (phase I/II study). Radiother Oncol 27, 22-29 (1993).
24. Sarkaria, J. N., Mehta, M. P., and Loeffler, J. S. et al. Radiosurgery in the initial management of malignant gliomas: survival comparison with the RTOG recursive partitioning analysis. Int J Radiat Oncol Biol Phys 32, 931-941 (1995).
25. Berger N. Malignant astrocytomas: Surgical aspects. Semin Oncol 21, 172-185 (1994).
26. Ashamalla, H., Ross, P., Ikoro, N. C. Consideration of fractionated stereotactic radiotherapy in patients with dentures. J Radiosurgery 2 (1999).
27. Gill, S. S., Thomas, D. G., Warrington, A. P., and Brada, M. Relocatable frame for stereotactic external beam radiotherapy. Int J Radiat Oncol Biol Phys 20, 559-603 (1991).
28. Graham, J. D., Warrington, A. P., Gill, S. S., and Brada, M. A non-invasive, relocatable stereotactic frame for fractionated radiotherapy and multiple imaging. Radiother Oncol 21, 60-62 (1991).
29. Hariz, M. I., Henriksson, R., Lofroth, P. O., Laitinen, L. V., and Saterborg, N. E. A non-invasive method for fractionated stereotactic irradiation of brain tumours with linear accelerator. Radiother Oncol 17, 57-72 (1990).
30. Ashamalla, H., Addeo, D., Ikoro, N. C., Ross, P., Cosma, M., Nasr, N. Commissioning and clinical results utilizing the Gildenberg-Laitinen adapter device for x-ray in fractionated stereotactic radiotherapy. Int J Radiat Oncol Biol Physics 56, 592-598 (2003).
31. 2, respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients. Int J Radiat Oncol Biol Phys 48, 1351-1358 (2000).
32. Langer, C., Ruffer, J., Rhodes, H., Paulus, R., Murray, K., Movsas, M., and Curran, W. Phase II Radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51, 113-119 (2001).
33. Fine, H. A., Kim, L., Royce, C., Duic, J. P., Cohen, L. J., Mitchell, S. A phase I trial of CC-5103, a potent thalidomide analog, in patients with recurrent high-grade gliomas and other refractory CNS malignancies. Proceedings of ASCO (Abst) 418 (2003).
34. Pereira, A., Stock, F., Gamboa, A. Temozolamide in children with progressive gliomas. Proceedings of ASCO (Abst) 3270 (2003).
35. Curran, W. J., Scott, C. B., and Horton, J. et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85, 704-710 (1993).
36. Huizing, M., Keung, A., Rosing, H., Van Der Kuij, V., Huinink, W., Mandjes, I., et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum- pretreated ovarian cancer patients. J Clin Oncol 11, 2127-2135 (1993).
37. Fetell, M., Grossman, S., Fisher, J., Eralanger, B., Rowinsky, E., Stockel, J., et al. Preirradiation Paclitaxel in glioblastoma multiforme: efficacy, pharmacology and drug interactions. J Clin Oncol 15, 3121-3128 (1997).
38. Baumert, F., Lutterbach, L., Bernays, R., Davis, D., and Heppner, P. Fractionated stereotactic radiotherapy boost after post-operative radiotherapy in patients with high-grade gliomas. Radiother Oncol 67, 183-190 (2002).
39. Cho, K., Walter, H., Gerbi, B., Higgins, P., McGuire, W., and Clark, B. Single dose versus fractionated streotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys 45, 1133-1141 (1999).
40. Fowler, J. F. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiat 62, 679-694 (1989).
41. Relling, M., Sandlund, J., Rivera, G., Hancock, M., Booyett, J., Schuetz, E., Evans, W. dverse effect of anticonvulsants on efficacy of chemotherapy for acute Lymphoblastic Leukemia. The Lancet 285-290 (2000).
42. Chang, S., Kuhn, J., Robins, H., Schold, S., Spence, A., Berger, M., Mehta, M., Pollack, I., Rankin, C., Prados, M. A phase II study of Paclitaxel in patients with recurrent malignant gliomas using different doses depending upon the concomitant use of anticonvulsants. Cancer 91, 417-422 (2001).
43. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. R. Stupp et al for the European Organization for Research and Treatment of Cancer Brain Tumor & Radiotherapy Groups and National Cancer Institute of Canada Clinical Trial Groups. NEJM 352, 987-996 (2005).
44. Schering-Plough Ltd. Temozolamide in the treatment of malignant glioma in the United Kingdom. A submission to the National Institute for Clinical Excellence (2000)
45. Yung, W. K., Albright, R. E., Olson, J., Predricks, R., Pink, K., Prados, M. D., et al. A phase II study of temozolamide vs. procarbazine. Proc Annual Meeting Am Soc Clin Oncol 19, A653 (2000).
46. Mosby's Drug Consult, Mosby, Inc 2005. Available at www.mdconsult.com.